Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $6.7 million.

  • SAB Biotherapeutics' Gains from Investment Securities rose 11797.62% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 11797.62%. This contributed to the annual value of $3.0 million for FY2024, which is 19399.64% up from last year.
  • SAB Biotherapeutics' Gains from Investment Securities amounted to $6.7 million in Q3 2025, which was up 11797.62% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Gains from Investment Securities peaked at $9.9 million during Q2 2023, and registered a low of -$1.7 million during Q2 2022.
  • Moreover, its 5-year median value for Gains from Investment Securities was $2.9 million (2025), whereas its average is $3.2 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 18880.36% in 2022, then skyrocketed by 1302042.04% in 2023.
  • SAB Biotherapeutics' Gains from Investment Securities (Quarter) stood at $3.9 million in 2021, then plummeted by 100.94% to -$36586.0 in 2022, then surged by 13020.42% to $4.7 million in 2023, then tumbled by 51.21% to $2.3 million in 2024, then soared by 192.63% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $2.9 million for Q2 2025, and $3.0 million during Q1 2025.